What do we know about atypical femoral fractures? Insights and enigmas

Joint Bone Spine

Volumn 78, Issue 6, 2011, Pages 568-571

  Audran, Maurice ^a   Cortet, Bernard ^b   Thomas, Thierry ^c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Atypical fractures; Bisphosphonates; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; PROTON PUMP INHIBITOR;

ATYPICAL FRACTURE; BONE SCINTISCANNING; BONE TURNOVER; DRUG USE; EARLY DIAGNOSIS; FEMUR FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REGISTER; RISK BENEFIT ANALYSIS; RISK FACTOR; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMORAL FRACTURES; HIP FRACTURES; HUMANS; OSTEOPOROSIS; PREVALENCE; RISK FACTORS;

EID: 84855935706     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.03.015     Document Type: Short Survey

References (21)

1. Siris E. Alendronate in the treatment of osteoporosis: a review of the clinical trials. J Womens Health Gend Based Med 2000, 9:599-606.
2. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018-2026.
3. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
4. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
5. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for bone and mineral research. J Bone Miner Res 2010, 25:2267-2294.
6. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010, 47:169-180.
7. Somford M.P., Draijer F.W., Thomassen B.J., et al. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009, 24:1736-1740.
8. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358:1304-1306.
9. Kwek E.B., Goh S.K., Koh J.S., et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39:224-231.
10. Lenart B.A., Neviaser A.S., Lyman S., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353-1362.
11. Schilcher J., Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009, 80:413-415.
12. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
13. Kim S.Y., Schneeweiss S., Katz J.N., et al. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. JBMR 2011, 26:993-1001.
14. Black D.M., Kelly M.P., Genant H.K., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362:1761-1771.
15. Vestergaard P., Schwartz F., Rejnmark L., et al. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int 2011, 22:993-1001.
16. Abrahamsen B., Eiken P., Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010, 95:5258-5265.
17. Weiss R.J., Montgomery S.M., Al Dabbagh Z., et al. National data of 6409 Swedish inpatients with femoral shaft fractures: stable incidence between 1998 and 2004. Injury 2009, 40:304-308.
18. Kelly M.P., Wustrack R., Bauer D.C., et al. Incidence of subtrochanteric and diaphyseal fractures in older white women: data from the study of osteoporotic fractures. J Bone Miner Res 2010, 25:FR0355.
19. Nieves J.W., Bilezikian J.P., Lane J.M., et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010, 21:399-408.
20. Wang Z., Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 2011, 26:553-560.
21. Siris E.S., Pasquale M.K., Wang Y., et al. Estimating bisphosphonate use and fracture reduction among US women aged 45years and older, 2001-2008. J Bone Miner Res 2011, 26:3-11.